PDS Biotechnology Corporation (PDSB) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 6 Buy, 1 Hold.
The consensus price target is $9.00, representing an upside of 749.1% from the current price $1.06.
Analysts estimate Earnings Per Share (EPS) of $-1.11 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1,079.45 vs est $-1.11 (missed -97147.7%). 2025: actual $-0.74 vs est $-0.80 (beat +7.5%). Analyst accuracy: 46%.
PDSB Stock — 12-Month Price Forecast
$9.00
▲ +749.06% Upside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for PDS Biotechnology Corporation, the price target is $9.00.
The average price target represents a +749.06% change from the last price of $1.06.
PDSB Analyst Ratings
Buy
Based on 7 analysts giving stock ratings to PDS Biotechnology Corporation in the past 3 months
EPS Estimates — PDSB
46%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1,079.45
vs Est –$1.11
▼ 99.9% off
2025
Actual –$0.74
vs Est –$0.80
▲ 8.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — PDSB
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
